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ABSTRACT
In radiation therapy, QA is an integral part of the IMRT treatment process.
This study evaluated two different QA modalities, a heterogeneous RANDO
phantom and the MatriXX Detector. The RANDO phantom study evaluated the
dosimetric accuracy of a helical TomoTherapy system which resulted in a
benchmark being established for dosimetric accuracy in heterogeneous
materials. The MatriXX study evaluated the performance of the MatriXX Detector
to determine if it could be used as a substitute for radiographic film in rotational
IMRT delivery techniques. At least twenty test cases were selected for each
study, and treatment plans were created using the Hi-Art TomoTherapy
treatment planning and delivery system. Kodak EDR2 radiographic films were
used and processed in batches of five films at least one hour after irradiation.
Horizontal profiles, vertical profiles, and Gamma pass/fail plots were calculated
for each test case. For the Gamma calculations, the threshold parameters were
set to a 3% dose difference and a 3-mm distance-to-agreement.
Analysis of the gamma pass/fail plots for the RANDO phantom study
showed the lung cases had 27.2% of the pixels exceeding gamma, while the
prostate patients had 14.7%. For the prostate test cases, only two of the films
had greater than 20% of the pixels exceeding the gamma threshold, while only
four of the lung test cases were below the 20% pixel threshold. Analysis of the
gamma pass/fail plots from the MatriXX study showed the percent of pixels
exceeding gamma was 10.8 ± 6.7% for the film verses 23.4 ± 13.8% for the
iv

MatriXX detector. The MatriXX appears to function well in high-dose low-gradient
regions and low-dose low-gradient regions. However, the MatriXX has difficulty
in regions with steep dose gradients due to volume averaging across the ion
chambers, and the coarse 7.62 mm center-to-center spacing of the chambers.
The RANDO phantom study analysis revealed that discrepancies between
calculated and measured dose distributions occurred at tissue-bone interfaces.
Further investigation will be needed to determine if these errors are due to film
response at heterogeneous tissue interfaces or from actual dose calculation
errors in the treatment planning system.
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PREFACE

This work is divided into six chapters. The first three chapters provide an
introduction to medical physics and radiation therapy, the clinical accelerators
used in this study, and the need for quality assurance and the modalities used.
The last three chapters cover the study set-up, results, and conclusion. Figures
corresponding to the study are found in Appendix I and tables in Appendix II.
Portions of this work were taken from supporting documents submitted to the
50th annual American Association of Physicists in Medicine meeting (AAPM).
Those documents were a collaboration between Dr. Chester Ramsey and me.
The RANDO phantom study was presented at the 50th annual AAPM meeting.
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Chapter 1
Introduction
1.1 Medical Physics and Radiation Therapy
The primary use of radiation therapy is to eliminate cancerous cell
populations. These cell populations are identified through an imaging modality
such as computed tomography (CT) or positron emission tomography (PET).
Once identified, these cell populations are exposed to fields of ionizing radiation
which damage the cells’ DNA eventually causing cell death. Ionizing radiation
can be delivered using a clinical linear accelerator or using radioactive materials.
Brachytherapy is a form of cancer treatment that uses small radioisotopes placed
inside a body cavity delivering gamma rays to the surrounding tissue. The most
common form of radiation delivery is through the use of a linear accelerator or
linac. Linacs deliver external beam radiation therapy by utilizing ionizing
radiation to penetrate a cancerous cell population and deliver a prescribed dose.
The prescribed dose is achieved in multiple fractions using a beam that is
shaped and delivered from multiple angles sparing as much healthy surrounding
tissue as possible.
Medical physics is an applied branch of physics that is concerned with the
safe delivery of radiation in order to achieve a therapeutic effect. As a patient
progresses through the cancer treatment process, many people play an active
role. The medical physicist’s role is to ensure radiation safety, help to develop
1

new therapeutic techniques, collaborate with the radiation oncologists to design
treatment plans, and to monitor equipment and patient procedures through
quality assurance [1].

1.2 Biological Effects of Radiation
When external beam radiation is chosen as the cancer treatment modality,
it is delivered using a linac. Both electrons and photons are used in cancer
treatment and are forms of ionizing radiation. Electrons are directly ionizing due
to the fact that they have enough kinetic energy to produce ionizing effects
through collisions as they penetrate through matter. This is better known as the
bremsstrahlung process. The electron interactions are provoked by the Coulomb
force between the electric field of the penetrating electron and the electric fields
of the orbital electrons and nuclei of atoms in the material. In radiation therapy,
electron energies range from 6MeV (mega-electron volts) up to 20MeV.
Photons are an indirect form of ionizing radiation. They liberate directly
ionizing particles, such as electrons, from matter during their interactions.
When photons are used in radiation therapy, their ionization ability is dominated
by the Compton process [2]. In the Compton process, the initial photon interacts
with a free electron in matter (an electron whose binding energy is very small
compared to the energy of the initial photon) transferring part or all of its energy
creating a fast electron. The fast electron then directly ionizes the surrounding
matter. If the initial photon didn’t transfer all of its energy, it will continue on a
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deflected path repeating the Compton process until it transfers all of its energy.
The fast electrons produced are able to ionize other atoms of the material, break
vital chemical bonds, and ultimately lead to the chain of events known as
biological damage [2].
The biologic effects of the x-rays can be a result of a direct action from the
fast electrons or an indirect action. A direct action is when the fast electron or
recoil electron directly ionizes the target molecule. An indirect action is when the
fast electrons interact with another molecule, such as water, to produce a radical
which interacts with the target molecule causing damage. The majority of
damage from x-rays is caused by indirect action to the target molecule’s DNA. In
radiation therapy, the allowable photon energies are 6MV (mega volts) to 18MV.

3

CHAPTER 2
CLINICAL ACCELERATORS
2.1 Basic Components
The prescribed dose of radiation is delivered using a linac. Linacs use
high-frequency electromagnetic waves to accelerate charged particles, such as
electrons, to high energies through a linear accelerating tube. The high-energy
electron beam can be used for treating superficial tumors, or it can be made to
strike a target producing x-rays for treating deep-seated tumors [3, 4]. A linac
has two main parts, a stand and the gantry. These two parts house all the
necessary internal components for operation. All linacs have the same basic
internal components. The components found in the stand are a cooling water
system, power supply, modulator, klystron/magnetron, waveguide, and circulator.
The electron gun, accelerating structure, and bending magnet are found in the
gantry. These components are shown in Figures 1 and 2. All figures are found
in Appendix I.
The cooling water system is a necessary element found in the base of the
stand which has two functions. First, it cools parts of the accelerator that
dissipate energy as heat, and secondly, it keeps the accelerator at a stable
operating temperature that is above room temperature in order to avoid
condensation from forming inside the accelerator. The power supply provides
direct (DC) power to the modulator, which produces high-voltage, flat-toped DC
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pulses that are microseconds in duration. These pulses are sent simultaneously
to the electron gun and the magnetron/klystron. The klystron/magnetron uses
the high-voltage DC pulses to produce pulsed microwaves which are carried via
the waveguide to the accelerating structure. Klystrons are used in high-energy
accelerators due to the fact that they can deliver higher power levels which are
required as the beam energy reaches greater than 12MV.
Although it may be more expensive, most linacs contain circulators. This
is a device that is inserted into the waveguide to stop microwaves from being
reflected back into the klystron/magnetron via the waveguide. If reflected
microwaves were able to reach the klystron, it would damage or detune the
structure resulting in the inability to produce microwaves. The electron gun is
located at the end of the accelerating structure near the waveguide. The electron
gun is a simple cathode that injects electrons into the accelerating structure.
These electrons are energized by the pulsed microwaves from the
klystron/magnetron. In the accelerating structure, the electrons are sent through
a linear series of cavities.
Most accelerating structures in present-day linacs are standing wave
accelerators due to the fact that they are much shorter than traveling wave
accelerating structures. The electric wave in a standing wave accelerator varies
in magnitude with time in a sinusoidal pattern, but remains stationary along the
axis (not advancing). This can be visualized by imaging a string fixed at both
ends, but oscillating up and down. As the electric field oscillates, the electrons
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are accelerated forward through the structure. With every pulsed microwave, a
new group of electrons are accelerated down the structure resulting in incident
and reflected waves. These incident and reflected waves combine to produce
standing waves that oscillate back and forth approximately one hundred times
during a five microsecond pulse [3]. The resulting standing waves have
stationary nodes that are located within every other cavity of the accelerating
structure and contain no electric field. Because there is no electric field in the
nodal cavities, they do not contribute to the acceleration of the electrons. These
cavities can therefore be moved off axis and shortened due to the fact that the
resonance of a cavity is not based on length, but diameter. This results in
shortening of the whole structure. After the electrons pass through the
accelerating structure, they are sent into the bending magnet which deflects the
electrons into a 270o loop focusing the electron beam.

2.2 The Gantry Head
The gantry head is a very important component of the linac. This is where
beam shaping, localizing, and monitoring take place [3]. The gantry head not
only contains the bending magnet, but the retractable x-ray target, flattening filter,
scattering foils, ionization chambers, and the collimators (primary and secondary)
as seen in figures 3 and 4. The retractable x-ray target is a thin, high Z material,
such as tungsten, that produces photons when bombarded with electrons. The
resulting photon beam is forward peaked meaning that the greatest intensity of
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photons are near the beam’s central axis and less intense elsewhere. To correct
the forward peaked beam, a very thin, conical metal absorber is placed in front of
the beam. This allows for absorption of photons from the more intense region of
the central axis resulting in a uniform dose distribution across the beam.
In electron therapy, the x-ray target and flattening filter are retracted and
the scattering foil is inserted into the path of the electron beam. The scattering
foil spreads out the focused beam coming from the bending magnet (figure 5).
The scattering foil is only used for electron therapy. As figure 5 shows, there is a
set of ion chambers that sit below the carousel for the flattening filter and
scattering foil. This set of ion chambers samples the radiation beam (photons or
electrons) as it passes through the head of the gantry. These ion chambers send
a signal back to the treatment control station reporting how much dose has been
delivered, and terminates the treatment when the prescribed dose has been
achieved. The purpose for having two ion chambers is simply to have two
independent measurements using one measurement to check the other.
The last important component of the gantry head is the primary and
secondary collimators. As seen in figures 4 and 5, the primary collimator sits just
below the x-ray target and initially shapes the photon beam, where as the
electron beam is still focused and passes through to the scattering foil. The
secondary collimator is a set of four, thick tungsten blocks that move in pairs.
These pairs are called jaws, and they help create sharp edges on all sides of the
electron or photon beam. These sharp beam edges are necessary to minimize
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penumbra. Penumbra is the region at the edge of the radiation beam where
dose changes rapidly as a function of distance from the beam axis. The jaws
can create field sizes up to 40 x 40 cm at a distance of 1 meter from the target.
A special case of collimation for treatment fields that are not rectangular in
shape is the use of a multileaf collimator (MLC) (figure 6). The MLC is built into
the gantry head and is found below the secondary collimator. It is the last
component that the beam passes through before entering the patient. The MLC
is typically made up of 80 (40 pairs) collimating blocks or leaves that are
independently motor driven to produce a field of any shape or size up to 40cm x
40cm. Each MLC is made out of tungsten, and collectively they have a leaf
thickness sufficient enough to block 98% of the photon beam at any given
position [4]. This allows for a more conformal treatment area that targets the
tumor volume and spares healthy surrounding tissue.

2.3 Varian Clinac 2100 EX
The Thompson Cancer Survival Center (TCSC) has two clinical linear
accelerators, one of which being a Varian Clinac 2100 EX (Varian Medical
Systems, Palo Alto, CA) and the other a HI-ART TomoTherapy linac
(TomoTherapy, Inc., Madison, WI). The Varian 21EX is the most prevalent type
of linac used in cancer treatment. The linac consists of the stand and gantry
which both house the same basic components and design as mentioned above.
In this machine, the standing waveguide is used in conjunction with a triode
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electron gun. A triode gun uses an additional grid to control the electron beam
current, which is normally held negative to the cathode, in order to cut off the
current to the anode. By using this design, the additional grid is able to control
the timing and magnitude of the current pulses injected into the accelerating
structure.
The Varian 21EX is klystron driven with allowable photon energies of 6
MV and 18 MV, and allowable electron energies ranging from 6 MeV to 20 MeV.
The linac has the capability of delivering dose from 100 to 600 MU/min to field
sizes ranging from as small as 0.5 cm2 up to 40.0 cm2. The Varian 21EX
employs a 120-tungsten leaf MLC consisting of fifteen 1cm thick leaves at the top
and bottom of the MLC carriage and thirty 0.5 cm thick leaves in the middle of the
MLC allowing for greater conformity around the target. The Varian 21EX has
image guidance capabilities referred to as PortalVision. Portal Vision is a
megavoltage imaging system used to ensure treatment plan verification, accurate
patient setup, and effective treatment delivery. PortalVision takes low energy xrays allowing clinicians to ensure the patient is properly set-up and the target
volume is in the treatment area [5].
The Varian 21EX employs a hydraulic treatment couch that is capable of
withstanding 300+ pounds and moves vertically and horizontally for patient
positioning. The Varian 21EX at TCSC was manufactured so that its isocenter is
located at 100 cm from the target source in the gantry head. The machine’s
isocenter is the imaginary intersection point in space of the axis of rotation of the
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collimator and the axis of rotation of the gantry. Patients are typically set up
using wall and ceiling mounted lasers placing the center of the target tissue at
isocenter.

2.4 Tomotherapy
Besides traditional linear accelerators, there is Tomotherapy (figure 7).
Tomotherapy is a linear accelerator with CT capability that is designed to deliver
a more conformal dose distribution for Intensity Modulated Radiation Therapy
(IMRT) treatments. The machine’s design is based largely on the concept of a
CT scanner. Internally, Tomotherapy geometrically employs a ring gantry design
with a binary multi-leaf collimator which rotates simultaneously with the couch’s
linear motion into the gantry bore. This results in delivery of a continuous, helical
(360o) dose pattern around the patient (Figure 8).
Tomotherapy contains all the major components of a traditional linear
accelerator and are arranged to fit inside the doughnut-like shape of the
machine. Tomotherapy employs a 3GHz magnetron to produce pulsed
microwaves instead of a klystron due to the low energy needed for treatment. A
6MV linear accelerator is mounted on the ring gantry which delivers an IMRT
treatment plan specific to each patient. Opposite the treatment head is a 13cm
thick lead counter weight attached to the gantry that acts as a rotating beam
stopper. Tomotherapy’s binary MLC consists of 64 tungsten leaves that are
individually 10cm high.
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The MLC defines the treatment field as a narrow open slit creating a wide
fan beam in the axial direction. The maximum width of the projected beam to the
axis is 40 cm, thus defining the maximum width for any patient treatment field as
40 cm. During treatment, the MLC leaves are either open or closed, and each
leaf moves independently to modulate and shape the beam as the gantry moves
around the patient. As the gantry rotates, Tomotherapy’s couch is designed to
move the patient at a constant velocity into the gantry bore and a maximum of
160 cm during the course of treatment. This defines the maximum length of any
patient treatment field to be 160 cm. Because Tomotherapy’s couch is designed
to move during treatment, a larger volume can be treated in one set-up.
The fan beam design of Tomotherapy allows radiation to be delivered in a
slice-by-slice manner. Tumor volumes are subdivided into a stack of slices that
are independently irradiated and collectively result in a 3D conformal dose
distribution. Tomotherapy employs 51 beams spaced roughly seven degrees
apart creating a continuous treatment field [6, 7]. Because of Tomotherapy’s
dynamic nature, it is critical that the couch, gantry, and MLC leaves are all in
sync.
Tomotherapy is an example of Image-Guided Radiation Therapy (IGRT).
The linac is designed with a built-in CT scanner which provides image guidance
in the treatment room. MVCT (megavoltage CT) imaging is performed prior to
each treatment to ensure the patient is correctly placed on the treatment couch,
and to confirm the tumor volume resides within the volume to be treated. The
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resulting MVCT images are fused and registered with the planning CT images at
the treatment console to determine if the patient needs to be repositioned for
treatment. Tomotherapy’s couch automatically adjusts the patient vertically and
longitudinally to account for roll. To account for yaw and pitch, patient
immobilization and positioning devices are used during treatment. The use of
IGRT before treatment has helped to identify the exact 3D location of tumor
volumes on a daily basis while sparing health surrounding tissue [6].
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CHAPTER 3
QUALITY ASSURANCE
In static external beam photon radiation therapy treatments, the photon
beam has a uniform intensity across the field. Because of this, a simple hand
calculation can be performed independent of the planning station to verify the
dose being delivered to the patient and the planning station dose are in
agreement. With recent technological advances, linear accelerators have the
ability to deliver IMRT treatments. IMRT treatments do not have a uniform
intensity across the field. Instead, the intensity is modulated by the MLC and
delivered from a multitude of beam angles to make an optimal composite dose
distribution.
Because the field is not uniform, a hand calculation is impossible to
perform, and therefore, the dose must be verified using another modality. A
protocol for patient-specific quality assurance (QA) was developed to solve this
problem and has become a major component of the IMRT clinical process [8].
The objective of this often time-intensive measurement process is to verify that
the prescribed dose is accurately being delivered to the target volume (tumor)
while sparing the healthy surrounding tissue. This study investigates two
different modalities for IMRT QA, evaluates the dosimetric accuracy of both a
helical tomotherapy system and Varian linac system, and investigates the
benefits of constant dose rate (CDR) VMAT delivery techniques.
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3.1 IMRT Treatments
The main objective of IMRT is to treat patients from a number of different
angles with non-uniform intensity beams that have been optimized to deliver a
high dose to the tumor and a very low dose to healthy surrounding tissue and
critical structures. IMRT is a radiation delivery technique that uses inverse
planning software to “shape” or conform a photon beam using a computer
controlled MLC. The MLCs are employed as compensators to modify the
intensity profile by moving in and out of the beam’s path in order to meet the
goals of a composite plan. This non-uniform fluence can be delivered to the
patient from any angle.
As with any radiotherapy plan, a 3D CT data set is needed, along with
image registration, critical structure contours, and beam selection and placement.
For IMRT, the planning software must have the ability to create beam segments
and contain an IMRT optimization algorithm. The user enters the dose criteria for
the target (tumor) and critical structures.

The software then optimizes the

intensity profiles for each beam and calculates the composite dose distribution.
After the generation of an acceptable IMRT plan, the intensity profiles for each
beam are electronically transferred to the linear accelerator’s delivery system [4].
There are three types of static IMRT delivery techniques, step-and-shoot,
sliding window, and intensity modulated arc therapy (IMAT). Of these three
techniques, step-and-shoot is the most widely used delivery technique, and the
technique used in this study. In the step-and-shoot delivery technique, the
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patient is treated with multiple beams that are individually subdivided into a
series of segments or different shapes. These segments are created by the
planning software, shaped using the MLC, and are delivered successively
without operator intervention. Each beam segment produces a unique intensity
profile, modulating the beam from segment to segment. After the completion of
all segments for one beam angle, the operator must move the gantry to the next
beam angle where the process repeats itself. The accelerator’s beam is not
turned on during MLC movement or gantry rotation resulting in its name, stepand-shoot IMRT. A subfield of step-and-shoot IMRT is dynamic-step-and-shoot.
In this method the accelerator’s beam is turned on throughout the delivery, even
when the MLC leaves are moving. Tomotherapy employs this method of stepand-shoot IMRT.
IMAT takes the idea of dynamic step-and-shoot IMRT one step further.
IMAT uses multiple beam angles to create a 360o arc treatment in the linac’s arc
therapy mode. As in dynamic step-and-shoot, each field (arc) is divided into
subfields of uniform intensity that collectively result in the desired intensity
modulation. The MLCs are constantly moving and shaping the beam as the
gantry rotates, while the accelerator’s beam stays turned on throughout the
treatment. One MLC subfield is delivered per gantry angle resulting in multiple
overlapping fields. The number of gantry angles is determined by the gantry
spacing set between each angle. The IMAT treatment planning algorithm divides
the two-dimensional intensity distribution created by inverse planning into
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multiple one-dimensional intensity profiles. These one-dimensional profiles are
then decomposed into discrete intensity levels that are to be delivered by the
subfields in a stack arrangement. The super imposed subfields create the
intensity modulation at each gantry angle [9].

3.2 VMAT Treatments
IMRT does deliver more conformal dose distributions while sparing
healthy surrounding tissue at the expense of longer treatment delivery times,
multiple beam angles, and increased monitor units (MU). In radiation therapy, a
monitor unit (MU) is a measure of machine output for a linear accelerator. Linear
accelerators are calibrated for a specific energy such that 1 MU gives an
absorbed dose of 1 centigray (cGy) at a depth of Dmax (or maximum dose) for a
field size of 10x10 cm2 for a source-to-axis (SAD) distance of 100 cm.
In an attempt to increase treatment efficiency, Volume Modulated Arc
Therapy (VMAT) was developed. VMAT is a special type of IMRT in which
radiation is delivered in single or multiple gantry rotations using a dynamic MLC
and modulated gantry speeds. There are two types of VMAT, constant dose rate
(CDR) and variable dose rate (VDR). CDR VMAT is when the dose rate is set at
one specific rate throughout the treatment delivery. For example, the dose rate
could be set to 300MU/min. VDR VMAT is when the dose rate changes
throughout the treatment delivery. In VDR, the dose rate could be programmed
to begin with 400 MU/min, then change to 200 MU/min at a specific gantry angle
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partially through the treatment, and end with 600 MU/min. The main objective of
VMAT is to deliver a treatment that is just as conformal, if not better, than a stepand-shoot IMRT treatment and hopefully, in less time. Before the invention of
VMAT, Tomotherapy was the only efficient arc treatment technique available.
With improvements in recent technology, conventional linacs will have the ability
to deliver 360o arc treatments with the instillation of the appropriate software
upgrades [10, 11].

3.3 Devices Used
In order to perform patient specific QA, the composite IMRT dose
distributions must be measured. Measurement of the dose distributions can be
achieved using a wide variety of techniques and devices known as dosimeters.
Some such devices include film (radiographic and radiochromic), ion chamber
arrays (MatriXX Detector), diode arrays, and Electronic Portal Imaging Devices
(EPIDs). Composite dose distributions are obtained by irradiating a test phantom
containing dosimeter(s).

3.3.1 Phantoms, Film, and Ion Chambers
Of all the available modalities, film is still one of the most versatile and
most frequently utilized measurement systems. When film is utilized as the
dosimeter, it is placed in a coronal, sagittal, or transverse plane inside a phantom
(figure 9). Because the film is irradiated using the same delivery sequence used
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to treat the patient, the dose given to specific anatomical structures (such as the
parotids, spinal cord, bladder, rectum etc…) can be evaluated.
Radiographic film and homogeneous solid water phantoms are commonly
used in patient-specific quality assurance testing. At TCSC Kodak radiographic
EDR2 film is commonly used. This type of film is used for doses delivered above
100 cGy, but below 600 cGy and comes sealed in a light safe jacket.
Radiographic film consists of three layers. The first layer is a transparent film
base made of polyester resin. The middle or second layer is a double emulsion
containing very small crystals of silver bromide which is topped by another
transparent film base. When the film is exposed to radiation (or visible light), the
silver bromide crystals undergo a chemical change forming a latent image.
When the film is developed, the crystals that have undergone a chemical change
reduce to small grains of metallic silver. As the film is fixed, the unaffected silver
bromide crystals are dissolved by the fixing solution resulting in a clear film. The
metallic silver crystals are unaffected by the fixing solution resulting in a dark
appearance, and thus a negative film results. The intensity of darkening on a film
depends on the amount of metallic silver created by the radiation energy
absorbed [12].
The darkness of the film can be measured by determining the optical
density or absorbance of the film using a densitometer. A densitometer consists
of a light source passing light through a diffusing screen incident on a small
aperture. The film being tested sits on top of the aperture. The light transmitted
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through the aperture and film is detected using a photocell. The photocell
collects all light coming through the aperture regardless of its direction.

The

transmitted light is known as It. The amount of light detected when no film is in
place is known as Io. The optical density is calculated by comparing these two
values using, log(Io/It). The optical density is affected by radiation exposure and
development procedures. To be a useful dosimeter, the film development must
be carefully monitored to ensure the correct chemical(s), time, temperature, and
agitation are taken into account. For each type of film used, a calibration of
density versus exposure should be performed [4, 12]. This will be discussed
further in chapter 5.
When using film as the dosimeter for patient specific QA, phantoms are
used to simulate the patient. There are primarily two types of phantoms,
homogeneous or heterogeneous. Homogeneous phantoms are made out of a
material, referred to as solid water, which is the same density as human soft
tissue. Solid water can come in the form of square blocks of different
thicknesses or in the shape of a cylinder with a specific thickness (figure 10).
Regardless of which form of solid water is used, the film is placed between two
pieces of the phantom in a coronal, saggital, or transverse plane. Upon
placement, the film is typically pricked with a pin to release any air bubbles in the
film jacket and to create fiducial marks on the film. There are very few
heterogeneous phantoms used in patient specific QA. One such phantom is the
RANDO phantom. This phantom simulates the different densities of bone, soft
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tissue, and air cavities in the body. These phantoms tend to be big, bulky, and
heavy making QA set-up difficult and time consuming. Due to the fact that the
treatment planning stations take into account patient heterogeneities, and not
much is known about the accuracy of heterogeneous phantoms, most institutions
do not use them regularly.
In conjunction with film and phantoms as QA modalities, ionization
chambers are frequently used to measure absorbed dose at a specific point in
the treatment volume. The ionization chamber is placed inside the phantom and
connected to an electrometer where the charge collection is displayed in
nanocoulombs. After irradiation, the ionization reading can then be converted
into dose using equation 1.
(1)

DQw is the absorbed dose to water at the point of measurement of the ion
chamber placed under reference conditions, M is the fully corrected ion chamber
reading, kQ is the quality conversion factor which converts the calibration factor
for a 60Co beam to that for a beam of quality Q, and N60CoD,W is the ion chamber
absorbed-dose-to-water calibration factor [4, 12, 13].
There are many different types of ionization chambers, but the most
widely used for patient specific IMRT QA are thimble chambers. A basic
ionization chamber is an enclosure containing two or more electrodes in which an
electric current is passed when the enclosed gas is ionized by radiation.
Specifically for this study, the gas used in thimble chambers is air and is ionized
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using a photon beam. The design of thimble chambers takes on the look of a
sewing thimble (figure 11). A low atomic numbered material is used for the walls,
which are typically 5 mm thick, in order to have the same effective number as
atmospheric air. Because of this, the materials of the wall and electrodes
produce ionization essentially similar to that produced in a free-air ionization
chamber. The inside of the solid chamber wall is made into an electrode by the
application of a special material (graphite, Bakelite, or plastic coated graphite and
Bakelite) to make it electrically conducting. The second electrode is a rod of low
atomic number material (graphite or aluminum) that is held at the center of the
thimble, but electrically insulated from it. In order to collect the ions produced
from irradiation of the chamber, a voltage is applied between the two electrodes.
Ion chambers do require periodic calibration [4, 12].

3.3.2 MatriXX Detector
Radiation therapy patients that are treated with Intensity Modulated
Radiation Therapy (IMRT) and Volume Modulated Arc Therapy (VMAT) must
have their calculated dose distributions verified with calculations and/or
measurements as stated earlier. In the past, radiographic film has typically been
used to measure and verify IMRT dose distributions as part of the quality
assurance process. Many radiation therapy departments have transitioned to
digital imaging systems, and the medical physicist(s) may no longer have access
to chemical-based “wet” film processors. As a result, there are now a variety of
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new media and devices that could potentially be used as a substitute for
radiographic film. One such device is the IBA MatriXX Detector (IBA Dosimetry
America, Bartlett, TN) (figure 12). The MatriXX is a vented ionization chamber
array with 1020 separate 4.5 x 5 mm2 ion chambers. Each chamber has a
volume of 0.08 cm3, and the detectors are spaced 7.62-mm center to center.
The chambers are arranged in a 32 x 32 grid with an active area of 24.4 cm 2.
The device itself has 3.3-mm of water equivalent material on the top surface, and
22-mm of backscatter material on the bottom. The MatriXX detector comes with
its own software that has analysis capabilities, but it was not used for the
analysis of this study [14].
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CHAPTER IV
Quality Assurance Clinical Set-up and
Experimental Specifications

In the discussion of the following studies regarding patient specific QA for
IMRT, specific clinical set-ups were used and will now be described.

4.1 Rando Phantom
Heterogeneous phantoms that simulate the different tissue densities in the
human body do exist, but are infrequently used for patient-specific IMRT QA.
The potential advantage of using heterogeneous phantoms is that the measured
dose distributions will more adequately reflect the clinical dose distributions in the
patients. The use of homogenous phantoms during IMRT quality assurance can
potentially mask errors that arise from limitations in the treatment planning
system’s modeling of density corrections. This study evaluated the dosimetric
accuracy of a helical tomotherapy system using an anthropomorphic RANDO
phantom for patient-specific QA. The results of this study allowed a benchmark
to be established for dosimetric accuracy in heterogeneous materials.
Patient-specific IMRT dosimetric verification was performed for twenty-four
patients using a male Alderson RANDO Phantom (The Phantom Laboratory,
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Salem, NY) (figure 13). The complete male RANDO phantom represents a 5’ 9”,
163 lb human male and is separated transversely into 2.5-cm slices. Each slice
consists of a natural human skeleton cast inside a material that is radiologically
equivalent to human soft tissue. The soft tissue simulates human muscle tissue
with randomly distributed fat. The lung portion of the phantom is made with a
lower density material simulating human lungs in a median respiratory state
molded to naturally fill the rib cage (figure14) [15]. For this study, the phantom
was divided into two separate sections: 1.) A lung phantom consisting of slices
14 through 19; and 2.) A pelvic phantom consisting of slices 26 through 35. The
setup of both phantom sections is shown in Figure 15.
In order to use the RANDO phantom for QA purposes, images of the
phantom needed to be imported into the treatment planning station. This was
done via a CT scan of each phantom (lung and pelvic). During “CT Simulation,”
the RANDO lung and pelvic sections were each placed in Vac-Lok cushions
(CIVCO, Orange City, IA) in order to hold the phantom sections together and to
help ensure a reproducible set-up for QA delivery. Vac-Lok cushions are
inflatable bags that are filled with small Styrofoam balls. Once inflated, patients
are typically placed on top of the bags in their specific treatment position. As the
bag is deflated, it can be molded around the patient creating an outline of their
shape and position. Vac-Lok cushions can also be used for phantoms, as in this
case. Rigid molds of each phantom set-up were created and used for each of
the patient-specific IMRT measurements.
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In order to perform patient specific QA, QA treatment plans have to be
created for each patient within the treatment planning station. This is
accomplished by using the QA tools on the planning station to overlay the
patient’s optimized IMRT dose distribution onto a section of phantom and
determine where the film should be placed if used as the dosimeter. The
treatment planning station takes into account the difference in densities between
the patient and the phantom and adjusts the dose distribution accordingly. If an
ionization chamber is going to be used, the treatment planning station can
calculate dose specifically for the location of the chamber in the phantom in order
to compare the calculated dose with the measured dose obtained from the
electrometer reading.
For the RANDO phantom study, treatment plans were created for 12
prostate and 12 lung patients using the Hi-Art TomoTherapy treatment planning
and delivery system. For the lung cases, the gross tumor volume or clinical
target volume (CTV) consisted of the primary tumor volume as visualized on CT
or PET/CT. For the prostate test cases, the prostate CTV included the prostate
gland and seminal vesicles. IMRT QA plans were created for each patient using
the corresponding phantom section (lung or pelvis), and the QA plans were
designed so the tumor volume from the patient resided in the same anatomical
site inside the RANDO phantom.
To deliver the planned QA procedure, the corresponding phantom section
was placed on the tomotherapy high-performance couch in the Vac-Lok cushion.
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For the prostate test cases, an A1SL thimble ionization chamber (Standard
Imaging, Middleton, WI) was placed in the phantom in the center of the target
volume. Ionization chamber readings were not taken for the lung cases due to
the random location of the tumor site within the lung. Kodak radiographic EDR2
film was placed in a transverse plane between two of the phantom slices for both
the prostate and lung cases. The film was taped to the inside surface of the
phantom to prevent film movement, and marked in three locations relative to the
machine isocenter (Figure 16). The phantom was then compressed using a belt
mechanism to eliminate gaps and air pockets between the phantom slices.
Once the phantom was correctly placed on the treatment table using the
wall mounted lasers and prior to irradiation, the phantom was imaged using
Tomotherapy’s MVCT system. The MVCT images were fused with the treatment
planning CT images using a pixel-by-pixel mutual information image registration
algorithm. From the image registration, the phantom was automatically
repositioned in the anterior-posterior, superior-inferior, and lateral directions by
the high-performance couch. In addition, the roll corrections were automatically
implemented by adjusting the treatment start angle within the treatment delivery
system. Yaw and pitch corrections were applied manually by moving and then
re-imaging the phantom until values of zero were obtained in the treatment
delivery system.
After applying all the set-up corrections and correcting for pitch and yaw,
the QA procedure was ready to be delivered. After irradiation, all EDR2 QA films
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were processed at least one hour after exposure in batches of five films. The
films were scanned using a Vidar 16 Dosimetry Pro (Vidar Systems, Herndon,
VA) and analyzed using both the Tomotherapy IMRT QA software and the RIT
dosimetry software (Radiological Imaging Technology, Colorado Springs, CO)
(figure 17). The calculated dose distribution obtained during the QA procedure
planning and the measured dose distribution obtained from irradiating the film
were registered with one another using a fiducial-based registration system with
the marks placed on the film prior to irradiation. In addition to the IMRT QA films,
calibration films were also shot. The calibration films were shot on the Varian
21EX using a 13 segment step-and-shoot sequence (see chapter 5 for more
information).

4.2 MatriXX Detector
The primary objective of this portion of the study was to determine if the
MatriXX detector could be used as a substitute for radiographic film in rotational
IMRT delivery techniques, such as Tomotherapy. In order to be useful for these
delivery techniques, the device must be angular independent in dose-response
and be capable of measuring composite dose distributions created during
rotation. In order to evaluate its performance, the MatriXX and radiographic film
measurements were taken using one Volume Modulated Arc Therapy (VMAT)
and nineteen Helical Tomotherapy treatment deliveries.
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Twenty random patients who were treated with helical tomotherapy during
the Fall of 2007 were selected for this comparative analysis. The original clinical
treatment plans were created and delivered using the TomoTherapy planning
and delivery system (Version 3.1). Treatment planning for the VMAT test case
was performed using the Pinnacle treatment planning system (Version 8.0,
Philips Medical Systems, Bothell, WA) and delivered on the Varian 21EX. The
VMAT treatment plan was created using Pinnacle’s Direct Machine Parameter
Optimization (DMPO) algorithm and was modeled and optimized as 51 equallyspaced fixed beams with one fixed MLC aperture per gantry angle. The plan was
modeled this way due to the fact that VMAT planning software had not been
developed yet.
The MatriXX detector was setup with a single 5 x 30 x 30-cm3 slab of
water-equivalent material (Solid Water, GAMMEX, Middleton, WI) centered over
the detector array to provide sufficient buildup during treatment delivery. The
device was positioned flat on the table top for coronal imaging with the
electronics pointing toward the end of the couch in order to avoid the radiation
field. Just as in the RANDO phantom experiment, the detector array in the
MatriXX was CT imaged. A 50-cm field-of-view and a slice thickness of 2-mm
were used as the imaging parameters. When the CT images were imported into
the Tomotherapy treatment planning system, they were automatically downsampled to 256 x 256 pixels in order to decrease computational times. As a
result, the final pixel dimensions for the MatriXX after import was 2-mm3. In order
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to maintain consistency in the VMAT experiment, the down-sampled CT images
of the MatriXX were also imported into Pinnacle and assigned as an IMRT
phantom. The Tomotherapy and VMAT quality assurance plans were created in
the respective planning systems by copying the patient’s plan to the CT images
of the MatriXX and re-computing the dose.
Measurements were performed with the MatriXX in the same setup and
configuration as in the CT phantom plan. The MatriXX was initially positioned on
the treatment table using the wall mounted lasers in the treatment room. For the
Tomotherapy test cases, the MatriXX was MVCT imaged and repositioned for
treatment using the same image-guidance technique as described in the RANDO
phantom study excluding the pitch and yaw corrections. In order to compare the
MatriXX with radiographic film, Kodak EDR2 film was placed on the surface of
the MatriXX under the 5-cm thick slab of solid water. The position of the film
relative to the machine isocenter was marked using a pin to prick the film jacket.
The position of the MatriXX relative to the machine isocenter was determined
relative to the center of the array. The same film calibration sequence used in
the RANDO phantom study was also used in this study. All MatriXX QA films
were processed at least one hour after exposure in batches of five films. The
films were scanned using a Vidar 16 Dosimetry Pro and analyzed using the RIT
dosimetry software.
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CHAPTER V
Quality Assurance Analysis and Results
5.1 RIT Software Analysis
Because IMRT treatments are too complex for QA hand calculations,
specific software is used in the IMRT QA analysis process. Radiological Imaging
Technology (RIT) is recognized as one of the leading companies in automated
IMRT QA analysis software. The RIT software has the ability to automatically
calculate a variety of methods including gamma analysis, vertical and horizontal
profiles, and addition and subtraction plots to analyze an IMRT treatment. If
radiographic film is used as the QA dosimeter, the RIT software requires several
initial tasks before the QA analysis can be performed. The software requires a
film calibration curve, importation of the dose map from the treatment planning
station (TPS), and registration between the film and the TPS dose map.

5.1.1 Film Calibration Dose to Density Curve
The film calibration curve is a calibration file created with in the RIT
software using actual dose measurements taken on the linac to assign film pixel
values a dose value. Several centimeters of solid water, a parallel-plate
ionization chamber, and film are placed on the couch of the linac and positioned
at the machine’s isocenter. Several centimeters of solid water are used to
prevent backscatter of radiation which would result in a false ionization chamber
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reading. The film and ionization chamber are irradiated using a 13-step-andshoot dynamic MLC file. This file is programmed to deliver 13 stripes of radiation
with each consecutive strip delivering slightly less radiation. The ionization
chamber is centered in the first stripe to acquire its ionization reading. Once the
reading has been recorded, the chamber has to be physically moved to the next
stripe in order to acquire the second stripe’s reading. This results in running the
dynamic MLC file 13 times to acquire ionization readings for all 13 stripes. Film
is only used the first time the MLC file is ran to prevent saturation. Once the film
is processed and scanned into the RIT software, the calibration curve can be
created (figure 18). Using the parallel dose calibration option within the software
allows the optical density of the 13 stripes on the scanned film to be assigned a
dose value which is obtained from the ionization readings. The readings are
converted to dose using equation 1. By creating this film calibration file and
applying it to any film during the analysis process, the software is able to assign
a dose value which corresponds to the film’s optical density. Without this
calibration file, the analysis software dose not know how to interpret the film’s
optical density, and therefore IMRT analysis can not be performed.

5.1.2 Film Registration
When analyzing IMRT QA films in RIT, registration between the film and
the TPS dose image must be performed in order to define a coordinate system
corresponding to both images. The TPS dose image is considered the
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calculated image, i.e. what the film or measured image should look like after
irradiation. The TPS dose image must be imported, and the irradiated film must
be scanned into the RIT software. Once the film has been scanned into the
software, the film calibration curve needs to be applied in order to assign dose to
the irradiated parts of the film. Once the scanned film has been calibrated, the
film and TPS dose image can be registered and analyzed. Registration between
the two is typically performed using a fiducial-based registration system. Marks
are placed on the film relative to the machine’s isocenter prior to being radiated
using a pin to prick the film jacket. This allows visible light through the light-safe
film jacket in those areas causing saturation of the film.
Once the film is developed these fiducial marks appear as white dots
(Figure 16). All films should be marked identically with respect to the machine’s
isocenter. By doing this, a coordinate-based template can be created in RIT.
This template is then applied to both the film and TPS dose image during the
registration process. The application of the template defines the corresponding
coordinate system that links the two images for IMRT QA analysis. Registration
can also be performed manually. This entails the user randomly selecting
corresponding points between the TPS dose image and the film. This form of
registration allows for a great deal of user error due to the limitation of the human
eye, and therefore is not frequently used or recommended.
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5.1.3 IMRT Analysis Profiles
After applying the calibration curve to the scanned film, and registering the
TPS dose image and the film, RIT can perform the automated IMRT QA analysis.
The software is programmed to compare the two images on a pixel by pixel basis
using different criterion for different profiles. For example, the Van Dyk criterion
is used for histograms or any of the gradient profiles comparing the patient
exposure to the TPS calculated exposure pixel by pixel [16].
Horizontal and vertical profiles are typically used in IMRT QA analysis to
detect any spatial discrepancies between the calculated and measured dose
distribution. After registering the images, this analysis plots a line profile spatially
corresponding to either a horizontal or vertical line in both images (Figure19).
For each profile there will be two lines, a solid line and a dashed line. One line
corresponds to the film (measured) dose distribution image, and the other line
corresponds to the TPS (calculated) dose distribution image. If the images are
registered properly and the QA was accurately delivered, the two lines should
virtually overlap. Due to small errors in MLC movement, QA set-up, and
registration, the lines may not be identical, but should be extremely similar in
shape. The horizontal and vertical profile lines can be moved in both images to
spatially evaluate different areas of the dose distribution.
Besides horizontal and vertical profiles, the gamma function is one of the
most widely used analysis profiles due to its ability to analyze high gradient
regions of the dose distribution. The gamma function combines a dose
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difference measurement with a distance to agreement (DTA) measurement to
assign a numerical value to each pixel in the distribution. A gamma value greater
than one indicates a failure of both measurements, and the pixel appears red in
color. The dose difference measurement is a user specified tolerance dependent
on the calculated dose from the TPS. For example, if the TPS calculated a pixel
value to be 10 cGy and the dose difference tolerance was set to +/- 3%, the
software would search the measured (film) pixel values until it found a pixel
between 9.7 cGy and 10.3 cGy. The DTA measurement is the distance between
a measured pixel (film) and the nearest calculated pixel (TPS) that contains the
same dose value. For this part of the gamma analysis, the user defines a
maximum search area (in mm) where the calculations are to be performed.
Adding onto the above example for the dose difference measurement, the
software is now constrained to a specific search radius. If the DTA criterion was
set to 3mm, the software would look for another pixel that was between 9.7 cGy
and 10.3 cGy, and was 3mm or less in distance from the original pixel. At TCSC,
we use a 3% dose tolerance and a 3mm distance to agreement as our gamma
criteria.
The calculation of gamma throughout the measured dose distribution
provides a visual analysis that quantitatively indicates the delivery accuracy
relative to the acceptance tolerances, and is displayed as a Gamma Pass/Fail
plot. This type of analysis is based on a technique created by Lowe et al of the
Mallinckrodt Institute [17-19].
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5.2 Rando Phantom Results
A study performed by Thomas et al published in “Medical Physics”
recently reported the results of IMRT verifications for ten patients planned and
treated with helical Tomotherapy. This study reported that nearly 92% of the film
pixels within the analyzed region of interest were within a gamma criterion of 2
mm and 2% [20]. Like most Tomotherapy users, Thomas et al used a test
phantom made of homogeneous water equivalent material which could have
masked potential errors that arise from limitations in the treatment planning
system’s modeling of density corrections. This study evaluated the dosimetric
accuracy of a helical tomotherapy system using an anthropomorphic RANDO
phantom for patient-specific QA. The results of this study allowed a benchmark
to be established for dosimetric accuracy in heterogeneous materials.
A 3mm DTA and 3% dose difference tolerance were used as the gamma
analysis criteria for the RANDO phantom study. The results using the RANDO
phantom were in stark contrast to those of Thomas et al. The mean gamma
index value and the percent of pixels exceeding the gamma threshold for the
RANDO phantom study are shown in Table I. Upon examination of Table I, it is
apparent that the calculated and measured dose distributions for the prostate test
cases had a better agreement than the lung cases. On average, the lung
patients had 27.2% of the pixels exceeding gamma, and the prostate patients
had 14.7% of the pixels exceeding gamma. For the prostate test cases, only two
of the films had greater than 20% of the pixels exceed the gamma threshold. In
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contrast, sixteen of the lung test cases had pixels that exceeded the gamma
threshold.
A close investigation of the calculated versus measured dose distributions
for the 24 test patients provides insight into the source of these differences. The
gamma pass/fail plots for the lung cases are shown in Figures 20-31, and the
prostate cases are shown in Figures 32-43. For the lung cases, the greatest
discrepancy between calculated and measured dose occurred at or near a
drastic change in tissue density. A discrepancy is defined as a pixel that fails to
meet the gamma criteria. Discrepancies appeared at the tumor-low density lung
tissue interface as well as the tumor-bone interface. All the lung cases except
numbers 4, 8, 9, and 12 had pixels that exceeded that gamma threshold limit of
20%. The sixteen patients who did not meet the 20% gamma threshold limit had
tumor volumes that were near one of the above mentioned interfaces. These
discrepancy regions were also high-gradient dose regions located near the edge
of the tumor volume. This area is known as the penumbra region where the dose
rapidly changes as a function of distance from the beam axis.
Despite the prostate calculated and measure dose distributions having
better agreement, the same trend identified in the lung cases was apparent in the
prostate gamma pass/fail analysis plots. The prostate cases had virtually no
discrepancies at the tumor-tissue interface. This is most likely due to the fact
that the prostate itself is soft tissue and is surrounded by soft tissue in the pelvis;
therefore there is not change in tissue density. The prostate cases had the
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greatest discrepancy at or near the tumor-bone interfaces in the pelvis (pubic
symphasis and ischial tuberoscities). Further inspection of the prostate cases
showed that prostate cases 2, 3, 8, and 11 displayed the greatest discrepancy in
the gamma analysis. The pixels that failed the gamma criteria were located
mainly at or near the pubic symphasis. The pubic symphasis is commonly
referred to as the pubic bone, and is located at the top of the prostate. The
horizontal and vertical profiles for all the RANDO test cases are shown in Figures
44-67. The profiles indicate that for the majority of the test cases the dose
distributions were spatially correct. Lung cases 3 and 11 and prostate case 3
seemed to have the greatest discrepancy spatially with the vertical profile. All
RANDO test case dose distributions were spatially aligned horizontally.
Because the RANDO phantom contains both bone and soft tissue, it is not
surprising that the results of the IMRT QA analysis in this study are different from
those obtained using homogenous phantoms. At the bone-tissue interface
(prostate and pubic symphasis), there is a greater amount of electron backscatter
as the beam interacts with the bone causing a slight dose enhancement in the
tissue adjacent to the bone, which is limited to a few millimeters [4, 21-27]. On
the transmission side of the tissue-bone interface, there is a slight forward scatter
of electrons from the bone. This forward scatter can cause a build-up of
electrons in the soft tissue giving rise to a dose perturbation. In contrast to
published results, it is a possibility that the backscatter effect could be causing
the gamma deficiencies due to the fact that previous tests only simulated

37

heterogeneous phantoms and were not true RANDO phantoms. Previous
reports used make-shift phantoms of balsa wood and different density materials
to simulate a heterogeneous phantom. Unlike the RANDO phantom, these
phantoms did not have real human skeleton, lung cavities, or water equivalent
material to represent human soft tissue. At low energies like that of
Tomotherapy, The American Association of Physicists in Medicine Task Group
65 reported that these dose enhancements should not cause great change in the
dose distribution [21].
Many reports have revealed that incorrect doses can be computed within
or near a low-density medium such as the lung, particularly when the field size is
small [28-32]. In the lung where there is a tumor-low density lung tissue
interface, Kornelson and Young state that there is a loss of lateral electronic
equilibrium when a high energy photon beam traverses the lung due to the face
that an increasing number of electrons travel outside the geometrical limits of the
beam. This causes a loss of dose on the beam axis and results in a less sharp
dose distribution profile. Kornelson and Young state this is only for small field
sizes (<6x6cm2) and for energies above 6MV [33]. Epps et al suggests that a
decrease in dose occurs at the surface beyond the cavity for large cavities such
as the lung and small field sizes [34, 35]. Both of these reports used
homogeneous phantoms and did not take into account contributions from tissuebone interfaces. Since the RANDO phantom QA plans were designed so that
the tumor resided inside the phantom in the same anatomical site as in the
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patient, some tumors were located at or near a tissue-bone interface. Taking into
account the electron scatter effect at the tumor edge and possible backscatter
effects from tissue-bone interfaces, introduces a possible cause as to why lung
cases 1, 2, 5, 6, and 11 failed to meet the gamma criteria.
While it is clear that the heterogeneities have an effect on the measured
dose distributions, it is unclear if these errors are due to film response at the
tissue-bone interfaces or from actual dose calculation errors [21-38]. In order to
rule out set-up error as a cause of the above mentioned discrepancies, the
reproducibility of the film dosimetry was tested for two prostate and two lung
cases. Repeat measurements were taken on three separate occasions, and the
films were processed on separate days from one another (Figure 68). The
standard deviation for the number of pixels exceeding the gamma threshold was
3.9%. For the prostate cases, the spatial location of the dose errors was not
consistent between measurements as shown in repeat measurement two. In
contrast, the spatial location of the maximum error for the lung cases was
consistent from measurement to measurement. Because the prostate
measurements were not consistent, set-up errors could not be ruled out as a
possible cause of the discrepancies.

5.3 MatriXX Detector Results
The primary objective of this portion of the study was to determine if the
MatriXX detector could be used as a substitute for radiographic film in rotational
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IMRT delivery techniques, such as Tomotherapy. In order to be useful for these
delivery techniques, the device must be angular independent in dose-response
and be capable of measuring composite dose distributions created during
rotation. A total of twenty helical tomotherapy test cases have been measured
and evaluated (12 prostates, 3 head & neck, 2 paraspinal metastasis, 1 brain
tumor, 1 esophageal tumor, and 1 mesothelioma). This group of patients
represented a broad spectrum of patients treated with rotational modulated
delivery.
After analyzing and comparing the gamma pass/fail plots for EDR2 film
and the MatriXX detector, it was shown that the EDR2 film had a much better
agreement between calculated and measured dose distributions than the
MatriXX data (Figures 69-88). From the gamma analysis, the percent of pixels
exceeding the threshold with a 3% dose difference tolerance and 3-mm DTA
criteria was 10.8 ± 6.7% for the EDR film verses 23.4 ± 13.8% for the MatriXX as
shown in Table II. For the EDR film, test case 14 was the only case to have
more than 20% of the pixels exceed the gamma threshold. In contrast, half of
the MatriXX test cases exceeded the gamma threshold by more than 20%.
While some test cases had large discrepancies between calculated and
measured dose distributions in both the film and the MatriXX data (Patients 2, 11,
and 14), the patient with the worst agreement using the MatriXX (Patient 8)
appeared normal in the film analysis.
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Further investigating the tumor volume size and the MatriXX
specifications, it was determined that the MatriXX appears to function well in
high-dose low-gradient regions and low-dose low-gradient regions. The gamma
pass/fail plots confirmed the MatriXX has difficulty in regions with steep dose
gradients, such as the penumbra region at the edge of the tumor volume. This is
likely due to a combination of two issues. The first issue is the fact that the
MatriXX performs volume averaging across the 4.5 x 5 mm2 chambers. The size
of the ion chambers used in the MatriXX seem small, but are actually quite large
in reference to tumor size and high-gradient regions. Because of this, errors
seem to be intensified. The second issue is the coarse 7.62 mm center-to-center
spacing of the chambers. In rotational IMRT delivery, the dose gradients are
frequently 5-10% per mm. Given the geometry and spacing of the individual
detectors, the dose can easily be out of tolerance in the gamma calculations [39,
40]. In this study, the MatriXX was set to interpolate the measured doses to a 3
mm resolution during data acquisition. Even with the interpolation between the
measured data points, it was very difficult to meet the 3-mm spatial DTA criteria
for the gamma pass/fail plots.
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CHAPTER VI
Conclusion

6.1 RANDO Phantom
The RANDO phantom study evaluated the dosimetric accuracy of a helical
tomotherapy system using an anthropomorphic RANDO phantom for patientspecific QA. The results of this study allowed a benchmark to be established for
dosimetric accuracy in heterogeneous materials. Using a 3mm DTA and 3%
dose difference tolerance, 12 prostate and 12 lung test cases were analyzed.
The results using the RANDO phantom were in stark contrast to those of
homogeneous phantom studies, especially for the lung test cases. While it is
clear that the heterogeneities of the RANDO phantom have an effect on the
measured dose distributions, it is unclear if these errors are due to film response
at the tissue-bone interfaces or from actual dose calculation errors. As shown
from the repeat measurements, set-up error can not be ruled out as a possible
contributor to the analysis discrepancies. The size, weight, and inefficient set-up
do not make the RANDO phantom a good modality for IMRT QA at the present
time. More investigation is needed before this becomes a routine modality for
IMRT QA.
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6.2 Matrixx Detector
The primary objective of the MatriXX study was to determine if the
MatriXX detector could be used as a substitute for radiographic film in rotational
IMRT delivery techniques, such as Tomotherapy. A total of twenty helical
tomotherapy test cases were analyzed using a 3mm DTA and 3% dose
difference tolerance. The results showed that the MatriXX appears to function
well in high-dose low-gradient regions and low-dose low-gradient regions. The
gamma pass/fail plots confirmed the MatriXX has difficulty in regions with steep
dose gradients due to volume averaging and the coarse 7.62 mm center-tocenter spacing of the chambers. Because of this, the dose can be out of
tolerance considering the dose gradients are frequently 5-10% per mm for
rotational IMRT. Based on the analysis of the MatriXX data, half of the patients
in this study would not have passed our institution’s patient-specific IMRT QA
testing. In contrast, only one patient would not have passed for measurements
taken with film. The MatriXX is limited in its spatial resolution and has difficulty
adequately verifying plans with steep dose gradients. At this time, the MatriXX
may not be the best modality for rotational IMRT delivery techniques. Further
investigation is needed.
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APPENDIX I - Figures

49

Figure 1: The external components of a traditional clinical linear
accelerator and treatment room [3].
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Figure 2: The internal components of a traditional linear accelerator [3].
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Figure 3: Gantry head components [3].
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Figure 4: Gantry head components below the bending magnet for a photon
beam [3].
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Figure 5: Gantry head components below the bending magnet for an
electron beam [3].
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MLC

Figure 6: MLC seen through the bottom of the collimator [4].
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Figure 7: The Tomotherapy linac at Thompson Cancer Survival Center.
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MLC

A

B
Figure 8: Tomotherapy’s binary MLC is shown in picture A. Picture B
shows the resultant delivery dose pattern around a patient as
Tomotherapy’s binary multi-leaf collimator rotates simultaneously with the
couch’s linear motion into the gantry bore.
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Figure 9: When quality assurance is performed in radiation therapy and film
is used as the dosimeter, a coronal, sagittal, or transverse plane is chosen
for the film placement.
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Figure 10: Solid water phantoms used in quality assurance tests, solid
water slabs, and a cylindrical phantom

Figure 11: A thimble ionization chamber commonly used in radiation
therapy quality assurance testing.
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Figure 12: The MatriXX detector from IBA Dosimetry used for IMRT quality
assurance in radiation therapy [14].
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Figure 13: The male Alderson RANDO phantom representing a 5'9", 163 lb
human male separated transversely into 2.5-cm slices [15].
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Figure 14: A 2.5 cm slice of the lung portion of the RANDO phantom. The
lung portion is made with a lower density material simulating human lungs
in a median respiratory state
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Pelvic
Phantom

Lung
Phantom

Figure 15: The Pelvic and Lung phantoms used in the RANDO phantom
study. The pelvic section consisted of slices 26-35, and the lung section
consisted of slices 14-19.
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Figure 16: Film fiducial marks made prior to irradiation relative to the
linac’s isocenter.
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Figure 17: The Vidar 16 Dosimetry Pro at the Thompson Cancer Survival
Center used to scan the processed films.
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Figure 18: Calibration curve created from 13-segment irradiated film
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Figure 19: Vertical and Horizontal profiles used to spatially compare the
calculated and measure dose distributions. If dose distributions are in
complete agreement, solid line and dashed line will be superimposed.
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Figure 20: Gamma Pass/Fail diagram for RANDO Lung patient 1 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 21: Gamma Pass/Fail diagram for RANDO Lung patient 2 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 22: Gamma Pass/Fail diagram for RANDO Lung patient 3 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 23: Gamma Pass/Fail diagram for RANDO Lung patient 4 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 24: Gamma Pass/Fail diagram for RANDO Lung patient 5 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 25: Gamma Pass/Fail diagram for RANDO Lung patient 6 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 26: Gamma Pass/Fail diagram for RANDO Lung patient 7 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 27: Gamma Pass/Fail diagram for RANDO Lung patient 8 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 28: Gamma Pass/Fail diagram for RANDO Lung patient 9 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 29: Gamma Pass/Fail diagram for RANDO Lung patient 10 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 30: Gamma Pass/Fail diagram for RANDO Lung patient 11 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 31: Gamma Pass/Fail diagram for RANDO Lung patient 12 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 32: Gamma Pass/Fail diagram for RANDO Prostate patient 1 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 33: Gamma Pass/Fail diagram for RANDO Prostate patient 2 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 34: Gamma Pass/Fail diagram for RANDO Prostate patient 3 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 35: Gamma Pass/Fail diagram for RANDO Prostate patient 4 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 36: Gamma Pass/Fail diagram for RANDO Prostate patient 5 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 37: Gamma Pass/Fail diagram for RANDO Prostate patient 6 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 38: Gamma Pass/Fail diagram for RANDO Prostate patient 7 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 39: Gamma Pass/Fail diagram for RANDO Prostate patient 8 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 40: Gamma Pass/Fail diagram for RANDO Prostate patient 9 using a
3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 41: Gamma Pass/Fail diagram for RANDO Prostate patient 10 using
a 3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 42: Gamma Pass/Fail diagram for RANDO Prostate patient 11 using
a 3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.

Figure 43: Gamma Pass/Fail diagram for RANDO Prostate patient 12 using
a 3mm DTA and 3% dose difference tolerance. The analysis region was
defined as the area of film receiving over 30% of the prescribed dose.
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Figure 44: Horizontal and Vertical profiles for RANDO lung patient 1.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 45: Horizontal and Vertical profiles for RANDO lung patient 2.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 46: Horizontal and Vertical profiles for RANDO lung patient 3.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 47: Horizontal and Vertical profiles for RANDO lung patient 4.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 48: Horizontal and Vertical profiles for RANDO lung patient 5.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 49: Horizontal and Vertical profiles for RANDO lung patient 6.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 50: Horizontal and Vertical profiles for RANDO lung patient 7.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 51: Horizontal and Vertical profiles for RANDO lung patient 8.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 52: Horizontal and Vertical profiles for RANDO lung patient 9.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 53: Horizontal and Vertical profiles for RANDO lung patient 10.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 54: Horizontal and Vertical profiles for RANDO lung patient 11.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 55: Horizontal and Vertical profiles for RANDO lung patient 12.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 56: Horizontal and Vertical profiles for RANDO prostate patient 1.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 57: Horizontal and Vertical profiles for RANDO prostate patient 2.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 58: Horizontal and Vertical profiles for RANDO prostate patient 3.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 59: Horizontal and Vertical profiles for RANDO prostate patient 4.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 60: Horizontal and Vertical profiles for RANDO prostate patient 5.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 61: Horizontal and Vertical profiles for RANDO prostate patient 6.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 62: Horizontal and Vertical profiles for RANDO prostate patient 7.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 63: Horizontal and Vertical profiles for RANDO prostate patient 8.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 64: Horizontal and Vertical profiles for RANDO prostate patient 9.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 65: Horizontal and Vertical profiles for RANDO prostate patient 10.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 66: Horizontal and Vertical profiles for RANDO prostate patient 11.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 67: Horizontal and Vertical profiles for RANDO prostate patient 12.
Horizontal and vertical profiles spatially evaluate the dose distribution
between the calculated and measured profiles.
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Figure 68: Repeat measurements for one prostate and one lung patient
testing film reproducibility using the RANDO phantom.
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Figure 69: Gamma Pass/Fail diagram for MatriXX study patient 1 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 70: Gamma Pass/Fail diagram for MatriXX study patient 2 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 71: Gamma Pass/Fail diagram for MatriXX study patient 3 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 72: Gamma Pass/Fail diagram for MatriXX study patient 4 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 73: Gamma Pass/Fail diagram for MatriXX study patient 5 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 74: Gamma Pass/Fail diagram for MatriXX study patient 6 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 75: Gamma Pass/Fail diagram for MatriXX study patient 7 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 76: Gamma Pass/Fail diagram for MatriXX study patient 8 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 77: Gamma Pass/Fail diagram for MatriXX study patient 9 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 78: Gamma Pass/Fail diagram for MatriXX study patient 10 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 79: Gamma Pass/Fail diagram for MatriXX study patient 11 using a
3mm DTA and 3% dose difference tolerance. The modality being tested is
Kodak EDR2 film. The analysis region was defined as the area of film
receiving over 10% of the prescribed dose.
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Figure 80: Gamma Pass/Fail diagram for MatriXX study patient 12 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 81: Gamma Pass/Fail diagram for MatriXX study patient 13 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.

117

Figure 82: Gamma Pass/Fail diagram for MatriXX study patient 14 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 83: Gamma Pass/Fail diagram for MatriXX study patient 15 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 84: Gamma Pass/Fail diagram for MatriXX study patient 16 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 85: Gamma Pass/Fail diagram for MatriXX study patient 17 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 86: Gamma Pass/Fail diagram for MatriXX study patient 18 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 87: Gamma Pass/Fail diagram for MatriXX study patient 19 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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Figure 88: Gamma Pass/Fail diagram for MatriXX study patient 20 using a
3mm DTA and 3% dose difference tolerance. The modality being tested in
the top image is Kodak EDR2 film. The modality being tested in the bottom
image is the MatriXX detector.
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APPENDIX II - Tables
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Table 1 : The mean gamma index and the percent of pixels exceeding the
gamma threshold with analysis criteria of 3mm DTA and 3% dose
difference tolerance for the 24 RANDO phantom study patients.
Lung Test Cases
Mean Gamma
Index

Percent Exceeding

1

0.82

30%

2

0.79

31%

3

0.71

23%

4

0.63

13%

5

1.13

49%

6

0.87

29%

7

0.82

30%

8

0.55

10%

9

0.64

16%

10

0.77

27%

11

4.57

55%

12

0.59

12%

Patient
Number

Gamma

Prostate Test Cases
Patient
Number
1

Mean Gamma
Index
0.55

Percent Exceeding
Gamma
6%

2

0.61

18%

3

0.62

14%

4

0.67

18%

5

0.65

19%

6

0.69

20%

7

0.55

9%

8

0.72

24%

9

0.57

8%

10

0.55

10%

11

0.74

23%

12

0.50

5%
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Table 2: The percent of pixels exceeding the gamma threshold with
analysis criteria of 3mm DTA and 3% dose difference tolerance for the 20
MatriXX study patients.

Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Average
Stdev

Film MatriXX
2.7%
5.8%
18.7%
45.1%
10.6%
8.6%
9.9%
13.9%
9.4%
10.2%
6.1%
21.5%
12.4%
21.7%
8.8%
58.4%
5.2%
26.9%
10.9%
17.2%
13.3%
42.2%
7.1%
13.8%
17.8%
15.5%
33.1%
44.1%
5.8%
32.6%
3.5%
23.1%
10.5%
21.7%
7.7%
8.7%
12.6%
13.4%
11.8% 22.8%
10.8% 23.4%
6.7% 13.8%
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